News

Ampio Pharmaceuticals to Present at the Emerging Growth Conference

  • ENGLEWOOD, Colo. , Sept. 26, 2023 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company") a pre-revenue stage biopharmaceutical Company focused on development of a potential treatment for osteoarthritis as part of its OA.201 program, today announced that its CEO, Michael A.
    09/26/2023

3 Biotech Stocks to Buy With Explosive Upside Potential

  • The biotech sector will always house stocks with explosive upside potential. The very nature of the sector ensures that will continue to be the case.
    06/22/2023
Profitability
Dividends
Income Statement
Balance Sheet
Cash Flow Statement
Symbol Frequently Asked Questions

Ampio Pharmaceuticals, Inc. (AMPE) can hold. Click on Rating Page for detail.

The price of Ampio Pharmaceuticals, Inc. (AMPE) is 1.8201 and it was updated on 2024-02-22 11:01:14.

Currently Ampio Pharmaceuticals, Inc. (AMPE) is in undervalued.

News
    
News

Which Strategies Are You Using With Penny Stocks in September?

  • Are you using these strategies for trading penny stocks right now? The post Which Strategies Are You Using With Penny Stocks in September?
    Sun, Sep. 04, 2022

Why These 3 Penny Stocks Are Climbing in Late April

  • Are these three penny stocks on your watchlist right now? The post Why These 3 Penny Stocks Are Climbing in Late April  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
    Fri, Apr. 22, 2022

Ampio Pharma Shares Fall As FDA Rejects Proposed Change In Knee Osteoarthritis Trial

  • Ampio Pharmaceuticals Inc (NYSE: AMPE) received written responses from the FDA pursuant to a Type C meeting request regarding the AP-013 Phase 3 trial results.  In March, Ampio announced data from the modified Intent-To-Treat (mITT) population (n=618) in the AP-013 study of Ampion in.
    Thu, Apr. 21, 2022

New Strong Sell Stocks for April 7th

  • AMPE, ANIK, and FAT have been added to the Zacks Rank #5 (Strong Sell) List on April 7, 2022.
    Thu, Apr. 07, 2022

New Strong Sell Stocks for April 1st

  • AKYA, AMPE, and BITF have been added to the Zacks Rank #5 (Strong Sell) List on April 1, 2022.
    Fri, Apr. 01, 2022
SEC Filings
SEC Filings
Press Releases
StockPrice Release
More Headlines
News

Ampio Pharmaceuticals, Inc. (AMPE) CEO Michael Martino on Q4 2021 Results - Earnings Call Transcript

  • Ampio Pharmaceuticals, Inc. (AMPE) CEO Michael Martino on Q4 2021 Results - Earnings Call Transcript
  • 03/29/2022

Why Ampio Pharmaceuticals Stock Is Rising Today

  • Ampio Pharmaceuticals Inc (AMEX:AMPE) shares are trading significantly higher Thursday following bullish analyst coverage. Alliance Global Partners analyst James Molloy initiated coverage on Ampio Pharmaceuticals with a Buy rating and announced a $4.50 price target, which is well.
  • 03/24/2022

Ampio (AMPE) Upgraded to Buy: Here's What You Should Know

  • Ampio (AMPE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
  • 12/14/2021

Down 25.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Ampio (AMPE)

  • The heavy selling pressure might have exhausted for Ampio (AMPE) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
  • 11/18/2021

Ampio Pharmaceuticals, Inc. (AMPE) Q3 2021 Results - Earnings Call Transcript

  • Ampio Pharmaceuticals, Inc. (AMPE) Q3 2021 Results - Earnings Call Transcript
  • 11/10/2021

Ampio Pharmaceuticals Strengthens Management Team and Board of Directors

  • ENGLEWOOD, Colo., Oct. 13, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for prevalent inflammatory conditions, today announced the appointments of Howard Levy, M.B.B.Ch.
  • 10/13/2021

Ampio Pharmaceuticals Receives Approval from the Drugs Controller General of India (DCGI) to Commence AP-019 Phase II Study in India

  • ENGLEWOOD, Colo., Sept. 21, 2021 /PRNewswire/ --  Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced regulatory approval from the Drugs Controller General of India (DCGI) of the Central Drugs Standard Control Organization (CDSCO) in the Phase II AP-019 clinical trial in India.
  • 09/21/2021

Best Penny Stocks For Retail Traders to Buy? 3 For Your List

  • Investing in penny stocks right now? Check these three small caps out for your watchlist The post Best Penny Stocks For Retail Traders to Buy?
  • 09/16/2021

Penny Stocks For Your Biotech Watch List In September 2021

  • Penny stocks that may be worth watching right now. The post Penny Stocks For Your Biotech Watch List In September 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
  • 09/15/2021

Ampio Pharmaceuticals Announces Top-line Results from AP-013 Phase III Study of Ampion in Adult Patients Suffering from Severe Osteoarthritis of the Knee (OAK)

  • ENGLEWOOD, Colo., Sept. 15, 2021 /PRNewswire/ --  Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced top-line results from AP-013, a randomized, saline-controlled, double-blind Phase III clinical study evaluating the efficacy of an intra-articular (IA) injection of Ampion™ in adults with pain due to severe osteoarthritis of the knee (OAK).
  • 09/15/2021

Ampio Pharmaceuticals Announces Important New Research Manuscript on Anti-Inflammatory Mode of Action

  • ENGLEWOOD, Colo., Aug. 13, 2021 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions for which there are limited treatment options, today announced a preprint version of a manuscript, "LMWF5A Demonstrates an Anti-Inflammatory Mode of Action and Similar Drug Targets to Dexamethasone in Activated PBMC," has been posted on In Review, a preprint platform hosted on Research Square.
  • 08/13/2021

Ampio Pharmaceuticals Reminds Stockholders to Vote Shares in Advance of 2021 Annual Meeting

  • ENGLEWOOD, Colo., Aug. 12, 2021 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions for which there are limited treatment options, reminds stockholders to vote on the proposals listed in the Company's proxy statement in advance of its upcoming annual meeting.
  • 08/12/2021

Ampio Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences

  • ENGLEWOOD, Colo., Aug. 11, 2021 /PRNewswire/ --  Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions for which there are limited treatment options, today announced that the company will host one-on-one investor meetings at the following investor conferences: H.C.
  • 08/11/2021

Why Penny Stocks Investors Are Bullish on These 3 Small-Caps

  • Why penny stocks investors are showing bullish interest in these 3 small-caps The post Why Penny Stocks Investors Are Bullish on These 3 Small-Caps appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
  • 08/05/2021

Here's Why Ampio Pharmaceuticals Stock Is Surging Today

  • A positive second-quarter earnings report and anticipation of further details to be discussed this afternoon helped this beaten-down biotech stock recover some previous losses.
  • 08/05/2021

Ampio Pharmaceuticals, Inc. (AMPE) CEO Mike Macaluso on Q2 2021 Results - Earnings Call Transcript

  • Ampio Pharmaceuticals, Inc. (AMPE) CEO Mike Macaluso on Q2 2021 Results - Earnings Call Transcript
  • 08/04/2021

Ampio Pharmaceuticals to Present at the American College of Toxicology 42nd Annual Meeting

  • ENGLEWOOD, Colo., July 29, 2021  /PRNewswire/ -- Ampio Pharmaceuticals  (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced details on the Company's poster presentation, "Efficient Applied Toxicology during COVID-19: A Preclinical Study that Advanced Clinical Use of Ampion," being given virtually at the American College of Toxicology 42nd Annual Meeting, November 14 to 17, 2021, at the Gaylord National Harbor in Washington, DC.
  • 07/29/2021

Ampio Pharmaceuticals to Present at the 14th International Congress on Systemic Lupus Erythematosus (LUPUS 2021) & 6th International Congress on Controversies in Rheumatology and Autoimmunity (CORA)

  • ENGLEWOOD, Colo., July 28, 2021 /PRNewswire/ --  Ampio Pharmaceuticals  (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced details on the Company's abstract presentation, "Significant Inhibition of the TLR7/CXCL10 Signaling Axis by LMWF5A in Monocytic Lineages; Implications for COVID-19 and Lupus Nephritis," being given virtually at the 14th International Congress on Systemic Lupus Erythematosus (LUPUS 2021) & 6th International Congress on Controversies in Rheumatology and Autoimmunity (CORA) on October 6-9, 2021.
  • 07/28/2021

Ampio Pharmaceuticals to Present at Aspen Lung Conference

  • ENGLEWOOD, Colo., July 27, 2021 /PRNewswire/ --  Ampio Pharmaceuticals  (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced details on the Company's poster presentation, "Inflammation and COVID Induced ARDS: Inhaled Ampion™ as a Therapeutic Option," being given at the 63rd annual Thomas L.
  • 07/27/2021

Ampio Pharmaceuticals, Inc. to Report Fiscal 2021 Second Quarter Financial Results and Provide Corporate Business Update

  • ENGLEWOOD, Colo., July 14, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced it will host a conference call to discuss financial results for the quarter ended June 30, 2021, and provide a corporate business update on Wednesday, August 4, 2021, at 4:30 pm EDT/ 2:30 pm MT.
  • 07/14/2021

Best Biotech Penny Stocks In Summer 2021? 7 For Your Watchlist

  • Are these the best biotech penny stocks to watch right now? The post Best Biotech Penny Stocks In Summer 2021?
  • 07/01/2021

Ampio Pharmaceuticals Announces Patient Randomization and Dosing in AP-019 Phase II Study of Inhaled Ampion in COVID-19 Respiratory Distress

  • ENGLEWOOD, Colo., June 25, 2021 /PRNewswire/ --  Ampio Pharmaceuticals  (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced randomization and dosing of patients in its multi-center AP-019 Phase II clinical trial, using inhaled Ampion™ in the treatment of respiratory distress due to COVID-19, is underway.
  • 06/25/2021

Ampio Pharmaceuticals, Inc. to Join the Russell 2000® Index and Russell 3000® Index

  • ENGLEWOOD, Colo., June 18, 2021 /PRNewswire/ – Ampio Pharmaceuticals (NYSE American: AMPE), a clinical stage biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced that the Company is expected to join the small cap  Russell 2000 ® Index and the broad-market Russell 3000 ® Index at the conclusion of this year's reconstitution of the Russell stock indexes, effective after the U.S. stock market opens on Monday, June 28, 2021, accordingly to a preliminary list of additions posted on June 4, 2021.
  • 06/18/2021

Ampio Provides Update on Osteoarthritis of the Knee (OAK) Program, Reiterates Compelling Data in Earlier Phase III Trials of Ampion in Severe OAK

  • ENGLEWOOD, Colo., June 17, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today reported newly integrated data from four of its earlier clinical trials with consistent inclusion, exclusion, and demographic populations utilizing Ampion for treating osteoarthritis of the knee (OAK).
  • 06/17/2021

Hot Penny Stocks to Buy? 3 to Watch As Vaccine Rates Hit New Highs

  • Best penny stocks to watch with vaccine rates higher than ever The post Hot Penny Stocks to Buy? 3 to Watch As Vaccine Rates Hit New Highs appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
  • 06/16/2021

Ampio Pharmaceuticals Receives Approval to Expand Enrollment of its AP-019 Phase II Study to India

  • ENGLEWOOD, Colo., June 15, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced it has received regulatory approval to expand enrollment of its AP-019 Phase II study to India.
  • 06/15/2021

Ampio Pharmaceuticals to Present at the 2021 International Society for Pharmaceutical Engineers Annual Meeting and Expo

  • ENGLEWOOD, Colo., June 14, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a clinical stage biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced details on the Company's poster presentation, "Pivoting From One to Multiple Production Platforms to Treat COVID," being given at the 2021 International Society for Pharmaceutical Engineers (ISPE) Annual Meeting and Expo in Boston, Massachusetts from November 1 st to 3rd, 2021.
  • 06/14/2021

Ampio Pharmaceuticals to Participate in the Alliance Global Partners' Virtual Summer Healthcare Symposium

  • ENGLEWOOD, Colo., June 11, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a clinical stage biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced that management will participate in a series of one-on-one meetings with institutional investors throughout the day at the Alliance Global Partners' Virtual Summer Healthcare Symposium on June 17, 2021.
  • 06/11/2021

Ampio Pharmaceuticals: Regulatory Process Taking Too Long

  • Ampio has existed for over a decade, and run more than a dozen trials for lead asset Ampion. Regulatory path is still unclear for osteoarthritis of the knee.
  • 05/23/2021

Ampio Pharmaceuticals to Present Poster at the International Society for Aerosols in Medicine (ISAM) 23rd International Congress

  • ENGLEWOOD, Colo., May 21, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a clinical stage biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced details on the company's poster presentation, "Regulatory Decisions during COVID-19: Efficient Nonclinical Inhalation Toxicology for a Clinical Program," being given at the 23rd International Congress of the International Society for Aerosols in Medicine (ISAM), in Boise, Idaho, May 22 to 26, 2021.
  • 05/21/2021

Ampio Pharmaceuticals Receives Investigational Review Board Approval for its Phase I Long COVID-19 Trial (AP-018)

  • ENGLEWOOD, Colo., May 10, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions for which there are limited treatment options, today announced that it has received Investigational Review Board (IRB) approval to commence enrollment in its AP-018 Phase I study using inhaled Ampion™ with patients exhibiting prolonged respiratory COVID-19 symptoms, known as long (or long-haul) COVID, or Post-Acute Sequelae of SARS-CoV-2.
  • 05/10/2021

Ampio Pharmaceuticals, Inc. (AMPE) CEO Mike Macaluso on Q1 2021 Results - Earnings Call Transcript

  • Ampio Pharmaceuticals, Inc. (AMPE) CEO Mike Macaluso on Q1 2021 Results - Earnings Call Transcript
  • 05/07/2021

Ampio Pharmaceuticals, Inc. Reports First Quarter 2021 Financial Results and Provides Business Update

  • ENGLEWOOD, Colo., May 5, 2021 /PRNewswire/ --  Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions for which there are limited treatment options, today reported quarterly financial results for the first quarter period ended March 31, 2021, and provided a corporate overview and business update.
  • 05/05/2021

Ampion™ Reduces All-cause Mortality in COVID-19 Respiratory Distress by Nearly 80%

  • ENGLEWOOD, Colo., April 27, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today revealed positive results in its AP-014 Phase I clinical trial utilizing inhaled Ampion in treating respiratory distress in patients as a result of COVID-19.
  • 04/27/2021

Ampio Pharmaceuticals, Inc. to Report Fiscal 2021 First Quarter Financial Results and Provide Corporate Business Update

  • ENGLEWOOD, Colo., April 21, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced it will host a conference call to discuss financial results for the quarter ended March 31, 2021 and provide a corporate business update on Wednesday, May 5, 2021 at 4:30pm EDT/ 2:30pm MT.
  • 04/21/2021

Research Shows Ampion™ Gene Regulation Mimics the Anti-Inflammatory Effects of Steroids, but without Adverse Effects

  • ENGLEWOOD, Colo., April 19, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions for which there are limited treatment options, today announced findings of pre-clinical research demonstrating that Ampio's lead drug candidate, Ampion™, provides some of the same anti-inflammatory effects as the steroid dexamethasone but without the significant adverse events associated with steroids.
  • 04/19/2021

Ampio Pharmaceuticals' Study Shows Ampion Inhibits a Key Inflammatory Pathway in COVID-19 and Lupus Nephritis

  • ENGLEWOOD, Colo., April 6, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced the results of a pre-clinical study demonstrating that Ampion inhibits an important pro-inflammatory pathway in the types of immune cells implicated in COVID-19 and Lupus Nephritis.
  • 04/06/2021

Ampio Pharmaceuticals is Building on its Progress in Tackling Osteoarthritis and COVID-19 Respiratory Issues

  • Ampio Pharmaceuticals (NYSE American: AMPE), a clinical stage biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, presented March 24, 2021 at the Benzinga Biotech Small Cap Conference. By Mark Gilman
  • 04/01/2021

Ampio Pharmaceuticals to Present at the International Society for Aerosols in Medicine (ISAM) 23rd International Congress

  • ENGLEWOOD, Colo., March 29, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a clinical stage biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced the company will present its findings on a poster entitled, "Regulatory decisions during COVID-19: Efficient nonclinical inhalation toxicology for a clinical program," at the upcoming 23rd International Congress of the International Society for Aerosols in Medicine (ISAM).
  • 03/29/2021

Ampio Pharmaceuticals Details Early Positive Results for Inhaled Ampion in COVID-19 Respiratory Distress

  • ENGLEWOOD, Colo., March 16, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, recently revealed preliminary positive results in its AP-014 Phase I clinical trial utilizing inhaled Ampion in treating respiratory distress in patients as a result of COVID-19.
  • 03/16/2021

Ampio Pharmaceuticals to Participate in the 33rd Annual Virtual ROTH Conference on March 15-17, 2021

  • ENGLEWOOD, Colo., March 10, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced that it has been invited to participate in the 33rd Annual ROTH Growth Conference being held virtually on March 15-17, 2021.
  • 03/10/2021

Why Ampio Pharmaceuticals Stock Is Jumping Today

  • Investors liked what they heard in the company's Q4 update.
  • 03/04/2021

Ampio Pharmaceuticals' (AMPE) CEO Mike Macaluso on Q4 2020 Results - Earnings Call Transcript

  • Ampio Pharmaceuticals' (AMPE) CEO Mike Macaluso on Q4 2020 Results - Earnings Call Transcript
  • 03/03/2021

Ampio Pharmaceuticals, Inc. to Report Annual 2020 Financial Results and Provide Corporate Business Update

  • ENGLEWOOD, Colo., Feb. 24, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced it will host a conference call to discuss the financial...
  • 02/24/2021

Ampio: Short-Term Triple-Digit Upside From Ampion's Progressing Phase 3 Drug Application

  • Ampio Pharmaceuticals, Inc. is a non-revenue producing biopharmaceutical company aiming to develop immunology-based therapies for inflammatory conditions. Ampio's pipeline consists of one late-stage therapeutic ("Ampion") across six inflammatory indications. Ampion is a novel biologic drug that regulates immune responses by suppressing inflammatory cytokines (proteins) and activating anti-inflammatory cytokines(tissue repair).
  • 02/12/2021

Why Ampio Pharmaceuticals Stock Tanked Today

  • Investors weren't comfortable with FDA feedback on the company's late-stage clinical trial.
  • 12/29/2020

Why MongoDB, Blink Charging, Ampio Pharmaceuticals, and Denali Therapeutics Stocks Tanked Today

  • 2020 is almost over. Maybe it's time to cash in -- and cash out?
  • 12/23/2020

Implied Volatility Surging for Ampio Pharmaceuticals (AMPE) Stock Options

  • Investors need to pay close attention to Ampio Pharmaceuticals (AMPE) stock based on the movements in the options market lately.
  • 12/15/2020

Ampio Pharmaceuticals, Inc. (AMPE) CEO on Q3 2020 Earnings Results - Conference Call Transcript

  • Ampio Pharmaceuticals, Inc. (AMPE) CEO on Q3 2020 Earnings Results - Conference Call Transcript
  • 11/06/2020

Brokerages Expect Ampio Pharmaceuticals, Inc. (NYSE:AMPE) to Announce -$0.02 Earnings Per Share

  • Analysts forecast that Ampio Pharmaceuticals, Inc. (NYSE:AMPE) will post ($0.02) earnings per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Ampio Pharmaceuticals’ earnings. Ampio Pharmaceuticals reported earnings of ($0.05) per share during the same quarter last year, which indicates a positive year over year growth rate of […]
  • 10/13/2020

Hot Mover of the Day: Brickell Biotech, Inc. (NASDAQ:BBI), Ampio Pharmaceuticals, Inc. (AMEX:AMPE) - Stocks Equity

  • Brickell Biotech, Inc. (NASDAQ:BBI) with the stream of 0.96% also noticed, India Ampio Pharmaceuticals, Inc. (AMEX:AMPE) encountered a rapid change of -2.91% in the last hour of Friday’s trading session. …
  • 10/10/2020

Ampio Pharmaceuticals Is Waking Up From Its COVID-19 Slumber, Approaching Potential Approval For Severe OAK (NYSEMKT:AMPE)

  • Ampio’s delayed pivotal phase 3 trial for severe OAK to resume. Strong hints of Ampion showing efficacy in COVID-19.
  • 09/16/2020

Glistering Stock: Ampio Pharmaceuticals, Inc. (AMPE), Facebook, Inc. (FB) - Stocks Equity

  • Ampio Pharmaceuticals, Inc. (AMEX:AMPE) with the stream of 6.80% also noticed, India Facebook, Inc. (NASDAQ:FB) encountered a rapid change of 0.15% in the last hour of Friday’s trading session. Ampio …
  • 08/28/2020

Ampio Provides Update on COVID-19 Clinical Trial Activities

  • Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, provides updates regarding the following clinical trials:
  • 08/19/2020

7 Penny Stocks Worth the Danger as Pandemic Catalyzes Growth

  • Investing in penny stocks is primarily the domain of highly risk-averse market participants. The risk profile of penny stocks is, of course, a double-edged sword: investors could lose a lot of money on them, yet could also reap massive returns. Many investors do consider penny stock purchases, but there are significant differences between trading them and higher-priced stocks. We reached out to Finance Professor Andrei Simonov at the Eli Broad College of Business at Michigan State University. We wanted to know whether he believes penny stocks to be a worthwhile investment, or if they are simply too risky to merit a position within one's respective portfolio. Simonov wrote:InvestorPlace - Stock Market News, Stock Advice & Trading TipsBy 'Penny Stocks', different people understand different things. Mostly, it is the term used for "microcaps" or "nanocaps" sometimes not listed on any national exchange, mostly illiquid with high trading cost (Bid-Ask Spread) and high price impact of the trade. That would be OK, but in many cases, this is paired with a lack of verifiable fundamental information. That makes Penny Stocks prone to manipulation and different kinds of fraud. I believe that most small individual investors should avoid those stocks. However, there are other examples. In 2009, Citigroup was formally a penny stock. Granted, it was a highly speculative investment at a time. But "fallen angels" like that are worth looking at.Professor Simonov clearly falls nearer the conservative end of the investor spectrum, which is understandable given his position. It's true that penny stocks often lack the transparency and long financial track records of large-cap stocks. And yes, penny stocks will remain subject to unscrupulous businessmen who maliciously issue penny stocks with fraudulent intent. Thus, investors do need to tread carefully and conduct as much due diligence as possible in this asset class. With common sense and due diligence penny stock investors can succeed.Volatility is high across markets. Interest rates are low. Investors are facing risk no matter where they look, and the investment landscape isn't what it was a few years ago. It may be time to give penny stocks another look. Nevertheless, there are not only 'fallen angels' as Simonov suggests, but also emerging champions within the sector also worthy of investor speculation. For the risk-averse investor here is a list of seven penny stocks worth the risk: * Boxlight Corporation (NASDAQ:BOXL) * Biocept Inc. (NASDAQ:BIOC) * Ampio Pharmaceuticals (NYSEAMERICAN:AMPE) * eMagin Corporation (NYSEAMERICAN:EMAN) * Lynas Corporation Limited (ASX:LYC) * Ucore Rare Metals Inc (OTCQX:UURAF) * Byrna Technologies (CNSX:BYRN) * 7 Dividend Stocks to Buy for Beginners to Income Investing Bear in mind that these stocks all have catalysts making them worth a look. In many cases, a single macroeconomic catalyst alone will trump all other factors when evaluating penny stocks. For example, the stock of a company that benefits from a new federal mandate may provide massive returns after years of lackluster performance. Therefore, an appetite for risk, some luck, and calculated hedging of bets can equate to massive windfalls in penny stocks. Boxlight Corporation (BOXL)Source: Shutterstock Education is undergoing a big transformation around the world. And technology has been the darling of the pandemic. Fotunately, EdTech sits squarely at the confluence of these two sectors. Investors are curious to know what stocks exist therein. Boxlight Corporation is one such company. Like most small-cap stocks, they aren't a household name. The company develops and services eLearning software for the classroom. Essentially, this firm will seek to establish itself as a leader in this burgeoning sector. Their solutions include interactive digital software, 3D printing and robotics STEM-related assets, and certifications to name a few. Among them is its MimioConnect cloud platform for remote teaching and learning.In early July the company announced the appointment of two board members who should provide great direction. They have multiple decades of experience at highly respected forms in the industry. The firm also recently won two excellence awards from Tech & Learning magazine. Boxlight corporation has developed a lot of software and resources which give it many avenues to rise. BOXL shares eclipsed $4 per share in early July after having traded around $1 for the previous year. Current shares are near $2.65. Biocept Inc. (BIOC)Source: Shutterstock Given the search for a Covid-19 vaccine, this list could have easily been all biotech penny stocks. There are many exciting sectors and stocks elsewhere, but here I will focus on two of them.Biocept is a company involved with a Covid-19 vaccine. Primarily, the company deals with cancer diagnostics. The firm is undertaking a vote in order to do a reverse split of its stock to raise its price above the NASDAQ $1 minimum closing bid requirement. It will be delisted if shareholders vote against the reverse split. Clearly it is a volatile stock, yet it serves a noble cause in an important market. * 10 Gaming Stocks That Will Power Through the New Normal Biocept's involvement with a vaccine is bound to pique the interest of speculative investors. The company has assembled a Covid-19 testing kit which will be available in Q3 2020. It is clear the company is attempting to remain relevant with these two latest moves. Ampio Pharmaceuticals Inc. (AMPE)Source: Iryna Imago / Shutterstock.com Ampio Pharmaceuticals is another biotech company that is throwing its hat in the Covid-19 ring. Its primary business is the development of anti-inflammatory drugs against disorders including osteoarthritis and diabetic eye issues. Ampio Pharmaceuticals has been active in the news in the last week as it relates to the pandemic. Additionally, Ampio's drug Ampion is being touted as a treatment against inflammatory syndromes related to Covid-19. The company published a study to that effect on July 20. On July 23 it enrolled patients into its Ampion Covid-19 Program. Should the results prove positive, this stock could rocket upwards from its current $1.17 price. eMagin Corporation (EMAN)Source: Shutterstock eMagin produces OLED microdisplay technology. Its organic light emitting diodes have application in military, consumer, medical, and industrial markets. The company's share price has been marching solidly upward in a consistent channel pattern for the past year, having risen from 32 cents to roughly $1.20. Such a 300% price increase is certain to entice more investors. * 7 Cybersecurity Stocks Hard At Work While We Work From Home Unlike some other penny stocks, EMAN shares have lots of financial information with which to conduct due diligence. Lynas Corporation Limited (LYC)Source: Shutterstock Lynas Corporation is a rare earths miner. There are many such companies, but what sets Lynas apart is one powerful catalyst: its strategic partnership with the U.S. Government. The U.S. Government is worried about its ability to produce strategically important minerals. It is particularly worried about its over-reliance on China for strategic minerals used across industries. To that end it has given a contract to Lynas, an Australian company with significant operations in Malaysia. The contract will allow Lynas to begin building a heavy rare earth separation facility in Texas. When completed, the facility will be the only plant which can separate such metals outside of China. This should make clear the strategic importance of the contract. This looks like a potentially huge business with massive growth potential. Shares currently trade in the $2.50 range but jumped on the news. The Texas facility design will be ready sometime in 2021. U.S.-China tensions will dominate headlines perhaps for several decades. Thus, shares in companies like Lynas, which benefit from that reality, have great potential to grow for a long period. Ucore Rare Metals Inc. (UURAF)Source: Shutterstock Ucore Rare Metals may rise for the same reason that Lynas has risen. However, this seems to be much more speculative. Lynas is clearly a legitimate company with real operations. Ucore has much less transparency behind it. Its website is very thin on information. Nevertheless, it is a stock to keep an eye on. * 10 Gaming Stocks That Will Power Through the New Normal The company has supposedly developed a new, efficient process for separating and purifying rare earth elements. If it indeed aligns itself with U.S. national defense and can deliver, it should rise exponentially. Byrna Technologies (BYRN)Source: Shutterstock Byrna Technologies is attempting to fill a void in the self-defense market. The company produces what looks like a gun that fires bullets but actually fires chemical irritant projectiles. Basically, pepper spray paint balls. The company is trying to fill the void between close-range pepper spray, and longer-range guns which fire lethal bullets. Further, the projectiles are non-lethal and are intended to disarm attackers, or give users ample time to flee. Byrna may have cornered a large market of American self-defense consumers. Many Americans do not want the responsibility and potential liability associated with gun ownership. However, they do want to protect themselves. Byrna's products neatly provide a solution for these consumers. Therefore Byrna may have identified a lucrative revenue base. Byrna's shares have traded below 50 cents CAD since 2013. Shares only recently rose to around 1.70 CAD in June. It may be time to give a few of these penny stocks a serious look. Investors are facing volatility with most any stock. Therefore, now may be as good a time as any to take a risk. These shares are a good place to start.
  • 07/31/2020

Ampio Starts Patient Enrollment in its Ampion COVID-19 Program

  • Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company" or "Ampio"), is a biopharmaceutical company focused on the development and advancement of immunology-based therapies for prevalent inflammatory conditions. As part of this program, the Company is actively working on the development of therapies for patients infected with the SARS-CoV-2 virus ("COVID-19").
  • 07/23/2020

Mid-Morning Market Update: Markets Down; AT&T Earnings Beat Estimates

  • Following the market opening Thursday, the Dow traded down 0.26% to 26,936.51 while the NASDAQ fell 0.11% to 10,692.02. The S&P also fell, dropping 0.04% to 3,274.73. The U.S...
  • 07/23/2020

Ampio Reports a Publication on the Potential Benefits of Ampion for Treatment of a New COVID-19 related Syndrome

  • Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the development and advancement of immunology based therapies for prevalent inflammatory conditions, today announced the publication "Insights into pediatric multi-system inflammatory syndrome and COVID-19."
  • 07/20/2020

Outlook of Diabetic Macular Edema (DME) 2020-2025 - Current Landscape and the Way Forward - ResearchAndMarkets.com

  • The
  • 07/13/2020

2020 Study into the Global Macular Edema Industry - Market Size and Drug Sales - ResearchAndMarkets.com

  • The
  • 07/02/2020

Ampio Pharmaceuticals (AMPE) Jumps: Stock Rises 8.7%

  • Ampio Pharmaceuticals (AMPE) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
  • 06/29/2020

-$0.04 Earnings Per Share Expected for Ampio Pharmaceuticals, Inc. (NASDAQ:AMPE) This Quarter

  • Wall Street brokerages expect Ampio Pharmaceuticals, Inc. (NASDAQ:AMPE) to post earnings of ($0.04) per share for the current quarter, according to Zacks. Zero analysts have issued estimates for Ampio Pharmaceuticals’ earnings. Ampio Pharmaceuticals reported earnings per share of ($0.03) in the same quarter last year, which suggests a negative year-over-year growth rate of 33.3%. The […]
  • 06/29/2020

Regeneron Pharmaceuticals : to Vigorously Defend Allegations Related to Contributions to a Patient Assistance Charity in 2013 and Early 2014 | MarketScreener

  • 06/24/2020

Regeneron's Latest Approval, And Other News: The Good, Bad And Ugly Of Biopharma

  • Regeneron's dupixent gets an approval. AbbVie walks out of Assembly Biosciences partnership. Ampio will begin a COVID-19 trial.
  • 06/22/2020

Ampio Pharmaceuticals (NYSEAMERICAN:AMPE) Shares Gap Up to $0.57

  • Ampio Pharmaceuticals Inc (NYSEAMERICAN:AMPE) gapped up prior to trading on Friday . The stock had previously closed at $0.33, but opened at $0.57. Ampio Pharmaceuticals shares last traded at $0.57, with a volume of 3,610,200 shares changing hands. Separately, Zacks Investment Research cut shares of Ampio Pharmaceuticals from a “buy” rating to a “hold” rating […]
  • 06/21/2020

Health News Roundup: Clover launches sixth Chinese COVID-19 vaccine trial; UK lowers Covid-19 alert level to 'epidemic' from 'exponential' and more

  • Italy sewage study suggests COVID-19 was there in December 2019 Scientists in Italy have found traces of the new coronavirus in wastewater collected from Milan and Turin in December 2019 - suggesting COVID-19 was already circulating in Northern Italy before China reported the first cases.
  • 06/19/2020

Ampio to study experimental drug in COVID-19 patients

  • U.S. drug developer Ampio Pharmaceuticals Inc said on Friday it would begin an early stage study of its experimental treatment, Ampion, in COVID-19 patients after it received regulatory clearance from the U.S. Food and Drug Administration.
  • 06/19/2020

Ampio to Start First Clinical Trial in COVID-19 Program

  • Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company"), is a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions. As part of this program, the Company is developing therapies for patients infected with the SARS-CoV-2 virus ("COVID-19").
  • 06/19/2020

Large caps deny they're being outgunned by smaller peers in health R&D - Stockhead

  • The journey of each individual medical treatment from idea to market requires the involvement of multiple parties big and small. The general consensus seems to be that it takes a big player to get a drug to market, which more often than not means the smaller players enact some sort of M&A deal to get …
  • 06/10/2020

Filled jobs fall 0.1 per cent: Aus shares close 0.1% higher

  • 10 Jun 2020 - The Australian share market fell at the open, but closed 0.1 per cent up at the end of trade. Filled jobs fell by 0.1 per cent and hours worked by 0.8 per cent between the December and March quarters.
  • 06/10/2020

What's Opthea eyeing now that it has two successful trials under its belt? - Stockhead

  • Having now proven its drug works on two eye diseases, Opthea (ASX:OPT) is looking to future treatment options. The immediate consideration for Opthea is a phase three study on Diabetic Macular Edema (DME), similar to its planned phase three study in wet-AMD. The company will spend the next few months planning the DME study but the wet-AMD …
  • 06/10/2020

Opthea (ASX:OPT) reports positive trial results: Aus shares 0.5% higher at noon

  • 10 Jun 2020 - The Australian share market opened lower but is now trading 0.5 per cent up at noon. Opthea (ASX:OPT) has reported positive Phase 2a trial results for its OPT-302 treatment in Diabetic Macular Edema.
  • 06/10/2020

Opthea's done it again: Its drug passed its DME clinical trial - Stockhead

  • Ten months since Opthea’s (ASX:OPT) drug proved itself against wet-AMD, it’s passed another clinical trial against Diabetic Macular Edema (DME). This morning the company conducted a 144-patient phase 2a clinical trial against DME, which is a smaller market than wet-AMD, but is similar in that it results in vision loss from fluid leakage in the …
  • 06/10/2020

Ampio Says Filed IND Applications For Ampion

  • 05/22/2020

Ampio Provides Update on COVID-19 Program

  • Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) is a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions. As part of this program, the company is developing therapies for patients infected with the SARS-CoV-2 virus ("COVID-19").
  • 05/22/2020

Ampio Provides Update on COVID-–9 Program

  • 05/22/2020

What You Must Know About Ampio Pharmaceuticals, Inc.'s (NYSEMKT:AMPE) Beta Value

  • If you're interested in Ampio Pharmaceuticals, Inc. (NYSEMKT:AMPE), then you might want to consider its beta (a...
  • 05/21/2020

Placenta Growth Factor Pipeline Review, H1 2020: Companies Involved in Therapeutics Development - ResearchAndMarkets.com

  • The
  • 05/21/2020

Ampio Reports Acceptance Of Publication On The Potential Benefits Of Nebulized Ampion For COVID-19 Coronavirus Patients

  • 05/11/2020

Ampio Pharma Reports Acceptance Of Publication On Potential Benefits Of Nebulized Ampion For Coronavirus Patients

  • 05/11/2020

Ampio Reports Acceptance of Publication on the Potential Benefits of Nebulized Ampion™ for COVID-19 Patients

  • Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the development of immunology based therapies for prevalent inflammatory conditions, today announced a manuscript accepted for publication in The Journal of Patient Safety in Surgery that showed Ampion treatment could improve clinical outcomes for COVID-19 patients.
  • 05/11/2020

Ampio Reports Acceptance of Publication on the Potential Benefits of Nebulized Ampion™ for ...

  • 05/11/2020

Global Macular Edema Therapeutics Market 2020 Segmentation Analysis, Key Players, Industry Share and Forecast by 2025

  • May 03, 2020 (CDN Newswire via Comtex) -- A recent comprehensive study titled Global Macular Edema Therapeutics Market 2020 by Company, Regions, Type and...
  • 05/03/2020

Diabetic Retinopathy Market by Type, Treatment, End-user and Region - Forecast to 2025 - ResearchAndMarkets.com

  • The "Diabetic Retinopathy Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025" report has been added to ResearchAndMarkets.com's offering.
  • 05/01/2020

Noven Financial Group, Inc. Buys iShares 7-–… Year Treasury Bond ETF, iShares '-7 Year ...

  • 05/01/2020

Finding The Kink In COVID-19's Armor - Preventing ARDS

  • A treatment is needed for ARDS. Remdesivir was touted by STAT. Antiviral efficacy and side effects are under scrutiny. CytoDyn is closest to a trial readout.
  • 04/28/2020

Ampio (AMPE) Looks Good: Stock Adds 5.2% in Session

  • Ampio (AMPE) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
  • 04/16/2020

Ampio (AMPE) Looks Good: Stock Adds 5.2% in Session

  • 04/16/2020

Implied Volatility Surging for Ampio (AMPE) Stock Options

  • Investors need to pay close attention to Ampio (AMPE) stock based on the movements in the options market lately.
  • 04/02/2020

Ampio Pharma Highlights FDA Application For Ampion To Treat Coronavirus-Induced Acute Respiratory Distress Syndrome Featured In FOX News Video

  • 04/02/2020

Ampio Pharmaceutical's Application to the FDA for a Clinical Study of Ampion™ to Treat COVID-19 Induced Acute Respiratory Distress Syndrome (ARDS) featured in FOX News (VIDEO)

  • Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a pre-revenue development stage biopharmaceutical company focused on the development of immunology based therapies to treat prevalent inflammatory conditions announced today that it was featured on a FOX segment titled, "Englewood pharmaceutical company looking to treat COVID-19 patients with anti-inflammatory drug," reported by an affiliated television station in Denver, Colorado. The primary cause of death associated with SARS-Cov-2 ("COVID-19") infection is Acute Respiratory Distress Syndrome ("ARDS"), and there are no approved treatments for ARDS or COVID-19. The segment featured the Company's application to the FDA to study the treatment of COVID-19 induced ARDS with nebulized Ampion.
  • 04/02/2020

Ampio Pharmaceutical's Application to the FDA for a Clinical Study of Ampion™ to Treat ...

  • 04/02/2020

Ampio Suspends Patient Enrollment In Phase 3 Study Of Ampion For Severe Osteoarthritis Of The Knee And Explores Other Options To Complete Trial As A Result Of Coronavirus Concerns

  • 03/24/2020

Ampio Suspends Patient Enrollment in its Phase 3 Study of Ampion for Severe Osteoarthritis of the Knee and Explores Other Options to Complete Trial

  • Ampio Pharmaceuticals, Inc. (NYSE American: AMPE; the "Company"), a pre-revenue development stage biopharmaceutical company announced today that it has suspended patient enrollment in its Phase 3 clinical trial of Ampion ("AP-013") for the treatment of severe osteoarthritis of the knee ("OAK"). The trial focuses on individuals with the most severely diseased OAK, which represents an underserved patient population typically excluded from clinical studies because of the intractable nature of their condition. The average and maximum age of a patient in the AP-013 clinical trial is 65 and 87 years old, respectively. The Centers for Disease Control and Prevention ("CDC") have indicated that older adults, 65 years and older, are at higher risk for severe illness during the current COVID-19 pandemic.
  • 03/24/2020

Ampio Says Is Preparing Expanded Access FDA Protocol To 'Study Nebulized Ampion as a Treatment for Moderate to Severe Acute Respiratory Distress Syndrome Associated with' Coronavirus

  • 03/24/2020

Ampio is Preparing an Expanded Access FDA protocol to Study Nebulized Ampion as a Treatment for Moderate to Severe Acute Respiratory Distress Syndrome Associated with COVID-19

  • Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a pre-revenue development stage biopharmaceutical company focused on the development of immunology based therapies to treat prevalent inflammatory conditions for which limited treatment options exist, announced today that it is preparing an expanded access FDA protocol to study potential benefit of nebulized treatment with Ampion in SARS-Cov-2 ("COVID-19") induced Acute Respiratory Distress Syndrome ("ARDS"), an immediately life-threatening condition.
  • 03/24/2020

Ampio Suspends Patient Enrollment in its Phase ' Study of Ampion for Severe Osteoarthritis of ...

  • 03/24/2020

Ampio Provides Corporate Update

  • Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) a development stage biopharmaceutical company, executing a Special Protocol Assessment ("SPA") Phase III clinical trial titled "Evaluating the Efficacy and Safety of Ampion™ to treat Adults with Pain Due to Severe Osteoarthritis of the Knee", today announced updates regarding the continued progress of its Phase III AP-013 clinical trial and receipt of its annual audit opinion.
  • 02/21/2020

Ampio Pharma 10-K Just Out; Includes Message About Co.'s Independent Registered Public Accounting Firm Having Expressed Substantial Doubt As To Co.'s Ability To Continue As A Going Concern

  • 02/21/2020

Ampio Provides Corporate Update

  • 02/21/2020

Here is What Hedge Funds Think About Ampio Pharmaceuticals, Inc. (AMPE)

  • Hedge funds are known to underperform the bull markets but that's not because they are terrible at stock picking. Hedge funds underperform because their net exposure in only 40-70% and they charge exorbitant fees. No one knows what the future holds and how market participants will react to the bountiful news that floods in each […]
  • 12/24/2019

Roth Capital Initiates Coverage On Ampio Pharmaceuticals with Buy Rating, Announces $4 Price Target

  • 12/19/2019

Ampio Pharmaceuticals shares are trading higher after Roth Capital Partners initiated coverage on the stock with a Buy rating.

  • 12/18/2019

Roth Capital Partners Initiates Coverage On Ampio Pharmaceuticals With Buy Rating, Says Mid-2020 Release Of AP-013 Data Will Be A 'Positive, Material Investment Catalyst'

  • 12/18/2019

Ampio Provides Update on AP-013 Phase III Clinical Trial and Annual Meeting Conference Call Number

  • Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) a development stage biopharmaceutical company, executing a Special Protocol Assessment (SPA) Phase III clinical trial titled "Evaluating the Efficacy and Safety of Ampion™ to treat Adults with Pain Due to Severe Osteoarthritis of the Knee", today announced updates regarding the continued progress of its Phase III AP-013 clinical trial and its manufacturing facility.
  • 12/04/2019

Ampio Provides Update on AP-…–' Phase III Clinical Trial and Annual Meeting Conference ...

  • 12/04/2019

Ampio execs subpoenaed over alleged insider trading

  • 11/07/2019

Private Capital Management Llc Buys Ampio Pharmaceuticals Inc, AT&T Inc, Comcast Corp, ...

  • 10/16/2019

Ampio Provides Update on Continued Progress of AP-013 Phase III Clinical Trial and Manufacturing Facility

  • ENGLEWOOD, Colo., Oct. 10, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) a development stage biopharmaceutical company, executing a Special Protocol Assessment (SPA) Phase III clinical trial titled "Evaluating the Efficacy and Safety of AmpionTM to treat Adults with Pain Due to Severe Osteoarthritis of the Knee," today announced updates of the continued progress with their Phase III AP-013 clinical trial and their "state-of-the-Art" manufacturing facility. "It is important to note," Ms. Cherevka continued, "in the three randomized single-injection studies previously run by the Company, both reduction in pain and improvement in function were significantly greater for KL 4 patients treated with Ampion vs saline.
  • 10/10/2019

Ampio Pharma Offers Update On Continued Progress Of AP-013 Phase 3 Trial, Manufacturing Facility

  • 10/10/2019

Ampio Retains Legal Counsel for Transaction Advisory Committee

  • ENGLEWOOD, Colo., Sept. 18, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) a development stage biopharmaceutical company, executing a Special Protocol Assessment (SPA) phase three clinical trial titled  "Evaluating the Efficacy and Safety of Ampion to treat Adults with Pain Due to Severe Osteoarthritis of the Knee", today announced that Cooley LLP has been engaged to represent Ampio with respect to a potential strategic transaction, as well as related matters.
  • 09/18/2019

Ampio Pharmaceuticals Updates Progress of SPA Clinical Trial

  • ENGLEWOOD, Colo. , Sept. 17, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE)   today announced the progress to date in the Company's special protocol assessment (SPA) phase three ...
  • 09/17/2019

UPDATE: Ampio Says Co. Consented/Enrolled 661 Patients Of Which 423 Have Been Injected, Added 52 Patients Approved For Injection

  • 09/17/2019

Ampio Pharmaceuticals Retains Financial Advisor and Appoints Transaction Advisory Committee

  • ENGLEWOOD, Colo., Aug. 22, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) a development stage biopharmaceutical company, executing a special protocol assessment (SPA) phase three clinical trial titled, "A Randomized, Controlled, Double-Blind Study to Evaluate the Efficacy and Safety of an Intra-Articular Injection of Ampion™ in Adults with Pain Due to Severe Osteoarthritis of the Knee," today announced that the Company has retained Torreya Partners LLC as a financial advisor and has appointed Willam Bindley and Bruce E. Terker to a newly formed Transaction Advisory Committee (TAC).
  • 08/22/2019

Ampio to explore strategic alternatives; shares up 3%

  • 08/22/2019

ThinkEquity Initiates Coverage On Ampio Pharmaceuticals With Buy Rating And $5 Price Target

  • 08/19/2019

Ampio Pharma Offers Update On Special Protocol Assessment Trial

  • 07/25/2019

Ampio Appoints Moss Adams LLP as the Company's New Independent Auditor

  • ENGLEWOOD, Colo., July 11, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a development stage biopharmaceutical company focused on the discovery and development of a novel therapy aimed at treating common inflammatory conditions for which there are limited treatment options, today announced that its Audit Committee and Board of Directors appointed Moss Adams LLP as the Company's new independent auditor. Moss Adams has served for over 100 years as a fully integrated professional services firm with over 3,200 professionals across more than 25 locations in the western United States.
  • 07/11/2019

Ampio Appoints Dan Stokely as the Company's new Chief Financial Officer

  • ENGLEWOOD, Colo., July 10, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a development stage biopharmaceutical company focused on the discovery and development of a novel therapy aimed at treating common inflammatory conditions for which there are limited treatment options, today announced that Dan Stokely has been appointed as Chief Financial Officer. Dan Stokely has more than 30 years of experience in finance and accounting and is a Certified Public Accountant.
  • 07/10/2019

New finance chief at Ampio

  • 07/10/2019

Have Investors Given Up On Antero Resources Corporation (AR), Ampio Pharmaceuticals, Inc. (AMPE)? | Post Analyst

  • Jul 05 was a weak volume day for , with an upside momentum. The trading capacity for the firm moved to 5877644 contracts. Over the past week, the average daily trading volume stood at about 8316980 shares per day. The regular session started at $5.44 but as the trading went on, the stock escalated, ending …
  • 07/08/2019

Ampio Pharmaceuticals Announces Closing of $12 Million Public Offering

  • The Company intends to use the net proceeds from this offering for the full cost of its AP-013 clinical trial, titled "A Randomized, Controlled, Double-Blind Study to Evaluate the Efficacy and Safety of an Intra-Articular Injection of Ampion in Adults with pain Due to Severe Osteoarthritis of the Knee," pursuant to its recently announced Special Protocol Assessment and for other general corporate purposes. The shares of common stock in this offering were offered on a reasonable best efforts, any and all basis pursuant to an effective shelf registration statement.
  • 06/19/2019

60 Biggest Movers From Yesterday

  • 06/18/2019

Ampio Pharmaceuticals Announces Pricing of Public Offering

  • The Company intends to use the net proceeds from this offering for the full cost of its AP-013 clinical trial pursuant to its recently announced Special Protocol Assessment and other general corporate purposes. ThinkEquity, a division of Fordham Financial Management, Inc., is acting as the exclusive placement agent for this transaction.
  • 06/17/2019

Mid-Afternoon Market Update: Crude Oil Down 1.5%; C&J Energy Services Shares Spike Higher

  • 06/17/2019

Ampio Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock

  • ENGLEWOOD, Colo., June 14, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) ("Ampio"), today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Ampio expects to grant the underwriters a 45-day option to purchase additional shares of common stock offered in the public offering. ThinkEquity, a division of Fordham Financial Management, Inc., is acting as sole book-running manager for the offering.
  • 06/14/2019

Ampio Regulatory and Clinical Update

  • According to Michael Macaluso, Ampio CEO, "The Company has identified and engaged 15 clinical sites for the trial (AP-013) and patient identification is underway. This pivotal trial seeks to enroll approximately 1,000 patients, with an interim look, to allow sample size adjustments, if required.
  • 06/14/2019

Ampio Pharmaceuticals shares are trading lower after the company reported a common stock offering with no disclosed size.

  • 06/14/2019

Ampio finance chief bids adieu

  • 06/13/2019

Ampio Pharma Offers Corporate, Clinical, Regulatory Updates

  • 05/22/2019

Ampio Pharmaceuticals, Inc. Option Alert: Jan, 2021 $1 Calls at the Ask: 800 @ $0.3 vs 1169 OI; Ref=$0.5001

  • 05/21/2019

Ampio Pharmaceuticals shares are trading lower after the company announced the FDA recommended that the company not start their confirmatory trial without obtaining FDA concurrence on the trial design.

  • 04/29/2019

CorMedix: Infected With Hype, Valuation Swollen

  • 04/25/2019

Ampio Pharmaceuticals May Offer, Sell Shares Of Common Stock From Time To Time Up To $24.65M Through Canaccord, Acting As Sales Agent

  • 04/15/2019

Ampio Pharmaceuticals Announces Resubmission of Special Protocol Assessment with FDA for a Confirmatory Phase III Clinical Trial of Ampion for Treatment of Patients Afflicted with Osteoarthritis of the Knee

  • 03/27/2019

Ampio Pharma Reports FDA Provided Guidance Co. 'should complete an additional trial of Kellgren Lawrence Grade 4 osteoarthritis of the knee patients with concurrent controls that would be carried out under a Special Protocol Assessment'

  • 03/06/2019

Research Report Identifies Wolverine World Wide, Viking Therapeutics, Ampio Pharmaceuticals, ...

  • 02/25/2019

Ampio Receives Initial Response From FDA Regarding Co.'s Proposed Trial

  • 02/06/2019

Helius Medical: A Failed Clinical Trial, Redacted Data, And Questionable Leadership, Points To An Ineffective Device

  • 01/29/2019

Ampio Pharmaceuticals shares are trading down 23% premarket after the Co announced that the FDA will require a new clinical trial of Ampion, the Co's lead drug for the treatment of severe osteoarthritis of the knee, to support its marketing application.

  • 12/13/2018

Ampio Pharma Announces the FDA's Office of Tissue and Advanced Therapies Will Provide Guidance by Mid-December if Ampio's Trial Portion of Ampion BLA is Complete Or Will Require an Additional Trial

  • 11/26/2018

88 Biggest Movers From Yesterday

  • 11/08/2018

Ampio Earlier Announced FDA Has Accepted A Type C Meeting Proposal From Co. And Scheduled Meeting Before End Of November

  • 11/07/2018

Bragar Eagel & Squire, P.C. is Investigating Certain Officers and Directors of Ampio ...

  • 10/30/2018

SHAREHOLDER ALERT: AMPE LCI PZZA SKX PM USAT COCP: The Law Offices of Vincent Wong Reminds ...

  • 10/23/2018

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in ...

  • 10/19/2018

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in ...

  • 10/12/2018

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of AMPE, NVRO ...

  • 10/10/2018

SHAREHOLDER ALERT: PDD AMPE NVRO LCI CBS PZZA LOGM SKX PM QRTEA: The Law Offices of Vincent ...

  • 10/05/2018

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in ...

  • 09/28/2018

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in ...

  • 09/21/2018

'The $GALT stock promoters (many of the same involved with the $AMPE pump and dump) have been salivating in anticipation of these meaningless single-arm combo data. Day traders enjoy!' -Tweet From STAT News' Adam Feuerstein

  • 09/20/2018

Ampio Pharmaceuticals' Chief Scientific Officer David Var-Or Retiring Effective September 30th

  • 09/04/2018

Pomerantz Law Firm Announces the Filing of a Class Action against Ampio Pharmaceuticals, Inc. ...

  • 08/31/2018

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ampio ...

  • 08/29/2018

Biotech Analysis Central Pharma News: Gemphire Pulls Plug, Ampio's FDA Despair, Paratek's Positive FDA Panel

  • 08/13/2018

Stocks Which Set New 52-Week Low Yesterday, August 9th

  • 08/10/2018

Mid-Afternoon Market Update: Yelp Jumps Following Strong Q2 Earnings; e.l.f. Beauty Shares Slide

  • 08/09/2018

Ampio Pharma Announces Common Stock Offering, No Size Disclosed

  • 08/08/2018

Ampio Pharma shares down 61% after the FDA said the company's trial for AP-0003-C was not adequate. The FDA is recommending Ampio performs a randomized trial

  • 08/07/2018

66 Biggest Movers From Friday

  • 08/06/2018

'Someone is paying for a new $AMPE stock promotion campaign on Twitter, Seeking Alpha, message boards and web sites like below:'-STAT's Adam Feuerstein Tweets

  • 07/27/2018

38 Biggest Movers From Yesterday

  • 07/24/2018

41 Biggest Movers From Friday

  • 07/23/2018

Ampio up 12% on rumored takeover

  • 07/20/2018

Ampio Pharmaceuticals Shares Up 15.7% For Session Despite No Company-Specific News Or Fundamental Catalyst To Justify Price Action; Watch For Technical Indicators And Price Action

  • 06/22/2018

Analysts Remain Bullish on Flexion Therapeutics

  • 06/12/2018

Ampio Announces 2 Peer-Reviewed Articles ON Clinical Application Of Ampion

  • 06/05/2018

Your Daily Pharma Scoop: 4 NDAs. CPRX, EXEL, ALPMY, ACOR

  • 05/31/2018

42 Biggest Movers From Yesterday

  • 05/30/2018

Ampio Awarded U.S. Patent For Treatment Of Joint Conditions That Provides Method Protection Until 2035 For Multiple Injections Of Ampion

  • 05/29/2018

Warrant You Glad You're Not Long Ampio?

  • 05/15/2018

UPDATE: Ampio Says Is Actively Pursuing Endeavors To Strengthen Its Balance Sheet

  • 05/14/2018

36 Biggest Movers From Yesterday

  • 05/01/2018

Your Daily Pharma Scoop: Intercept's OCA, MediciNova In NASH, Pulse Biosciences Data

  • 04/16/2018
Unlock
AMPE Ratings Summary
AMPE Quant Ranking